Clinical Trial Update: Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating an investigational melanoma vaccine that uses CD40 activation and TLR agonists to target neoantigens and shared antigens. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Uveal Melanoma

Drugs mentioned

• Investigational melanoma vaccine targeting neoantigens and shared antigens with CD40 activation and TLR agonists

Snippet

Sponsor: Craig L Slingluff, Jr | Conditions: Melanoma, Ocular Melanoma | Phase 1, Phase 2 | Status: COMPLETED